Clinical Trial Update: Pharmacokinetics, Safety and Tolerability of Aliskiren (SPP100) in Patients With End Stage Renal Disease on Hemodialysis and Matched Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics, safety and tolerability study comparing aliskiren (SPP100) in patients with end-stage renal disease on hemodialysis to matched healthy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• Aliskiren (SPP100) (aliskiren)

Snippet

Sponsor: Novartis | Conditions: End Stage Renal Disease | Phase 1 | Status: COMPLETED